Nature Medicine | Bispecific Innate Immune Cell Engager Targeting CD30 Combined with Allogeneic NK Cells for Treating Refractory Lymphoma

This study provides a novel 'off-the-shelf' NK cell therapy strategy for patients with relapsed/refractory CD30+ lymphoma without requiring HLA matching, significantly improving the complete response rate in this patient population and offering important insights for the design of immunotherapies for hematologic malignancies.

 

Literature Overview

The article titled 'Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial,' published in Nature Medicine, systematically investigates the clinical safety and preliminary efficacy of combining umbilical cord blood-derived, cytokine pre-activated and expanded NK cells with the bispecific antibody AFM13 (pre-complexed as AFM13-NK) for treating CD30+ refractory lymphoma. The study validates the high response rate and favorable tolerability of this strategy in a real-world, highly refractory patient cohort, laying the foundation for larger follow-up trials.

Background Knowledge

Currently, although the anti-CD30 antibody-drug conjugate brentuximab vedotin (BV) and anti-PD-1 checkpoint inhibitors (CPI) have improved outcomes in Hodgkin lymphoma, patients who are resistant to both BV and CPI still lack effective treatment options and face extremely poor survival outcomes, representing an unmet clinical need. These patients often exhibit a highly immunosuppressive tumor microenvironment, leading to functional exhaustion of endogenous NK and T cells. Although CAR-T cells have achieved breakthroughs in hematologic malignancies, CD30-targeted CAR-T therapy has shown limited efficacy and significant toxicity in Hodgkin lymphoma. Additionally, autologous cell therapies face challenges such as long manufacturing times, high costs, and impaired T-cell function. Therefore, developing 'off-the-shelf,' safe, and effective allogeneic immune cell therapies has become a key breakthrough. This study utilizes the CD30/CD16A bispecific antibody AFM13 to redirect natural killer (NK) cells to CD30+ tumor cells, overcoming the limitation of NK cells lacking antigen specificity. It selects NK cells derived from umbilical cord blood due to their easy availability, lack of strict HLA matching requirements, and low risk of graft-versus-host disease (GVHD), offering a novel approach to address current bottlenecks in immunotherapy.

 

 

Research Methods and Experiments

The study employed a single-center, investigator-initiated phase 1 clinical trial design, enrolling 42 patients with CD30+ lymphoma resistant to both BV and CPI. After lymphodepleting chemotherapy with fludarabine and cyclophosphamide, patients received NK cells derived from different umbilical cord blood units, pre-activated and expanded with IL-12/IL-15/IL-18, pre-complexed with the AFM13 antibody (AFM13-NK). The primary endpoints were safety and determination of the recommended phase 2 dose (RP2D), while secondary endpoints included overall response rate (ORR), complete response rate (CR), event-free survival (EFS), overall survival (OS), and cell persistence. The study used multicolor flow cytometry, mass cytometry (CyTOF), and immunohistochemistry to deeply analyze the phenotype, function, and in vivo kinetics of the infused NK cells. CyTOF analysis revealed that shortly after infusion, a highly activated Cluster 4 (C4) NK cell phenotype emerged, expressing high levels of activation, proliferation, and tissue-homing markers, which gradually transitioned to the persistent Cluster 5 (C5) phenotype, suggesting a dynamic process of in vivo activation and functional maintenance. Additionally, immunohistochemical analysis of paired tumor samples assessed potential immune escape mechanisms, such as changes in the expression of HLA-E, MICA, and CD30.

Key Conclusions and Perspectives

• The AFM13-NK cell therapy demonstrated exceptional efficacy in 42 highly refractory patients, achieving an ORR of 92.9% and a CR rate of 66.7%, indicating that this strategy can effectively overcome multi-drug resistance. [Data discovery] + [Implications for future immunotherapy design in hematologic malignancies]
• No cytokine release syndrome (CRS), neurotoxicity, or graft-versus-host disease (GVHD) was observed, confirming the safety advantages of allogeneic NK cell therapy. [Data discovery] + [Implications for future safety assessments of cell therapies]
• Infused NK cells were detectable in vivo for up to 3 weeks and were able to home to tumor sites; their phenotypic dynamics (C4→C5) revealed a balance between activation and persistence, providing a basis for optimizing dosing regimens. [Data discovery] + [Implications for future NK cell kinetics research]
• Tumor cells continued to express CD30 post-treatment, and there was no clear evidence of immune escape through upregulation of inhibitory ligands (e.g., HLA-E) or downregulation of activating ligands (e.g., MICA), supporting the feasibility of CD30 as a stable therapeutic target. [Data discovery] + [Implications for future target selection]
• No anti-HLA antibodies were detected even in HLA-mismatched settings, and AFM13 binding showed no difference between donor and recipient NK cells, supporting the potential for repeat dosing with 'off-the-shelf' products. [Data discovery] + [Implications for future development of universal cell products]

Research Significance and Prospects

This study sets a new benchmark for the development of 'off-the-shelf' NK cell therapies, with its high response rate and favorable safety profile providing strong support for subsequent phase 2 trials. Compared to autologous CAR-T, this strategy avoids T-cell exhaustion and manufacturing failures and offers a shorter production cycle, enabling immediate treatment. The results underscore the central role of CD16A as an NK cell activation receptor in the design of bispecific antibodies, providing a template for developing more innate immune cell engagers targeting different tumor antigens.

Although some patients eventually relapsed, 11 patients maintained CR for 14–40 months, suggesting the possibility of deep and durable remissions. Future studies should explore strategies such as genetic engineering (e.g., IL-15 expression) to prolong in vivo persistence of NK cells, thereby reducing treatment cycles and improving long-term cure rates. Furthermore, the application of this strategy in non-Hodgkin lymphoma warrants further investigation.

 

 

Conclusion

This study successfully translates fundamental immunological principles into clinical practice, demonstrating the significant efficacy and safety of allogeneic cord blood-derived NK cells pre-complexed with AFM13 in patients with refractory CD30+ lymphoma. This 'off-the-shelf' therapy not only offers new hope for patients with dual resistance but also advances the development of universal cell-based immunotherapies. From bench to bedside, the study validates the feasibility of redirecting innate immune cells using bispecific antibodies, with the core mechanism—bridging CD16A and CD30 via AFM13—providing a robust framework for developing similar strategies against other hematologic and solid tumors. Although long-term survival requires longer follow-up, the high complete response rate and cases of durable remission suggest this therapy could become a key component of future lymphoma treatment paradigms, especially for patients ineligible for CAR-T or transplantation. This study establishes a critical cornerstone in the immunotherapy care framework for hematologic malignancies, marking a pivotal step toward mainstream clinical adoption of 'off-the-shelf' NK cell therapies.

 

Yago Nieto, Pinaki Banerjee, Indreshpal Kaur, Elizabeth J Shpall, and Katayoun Rezvani. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Nature medicine.